NKGNW
NKGen Biotech, Inc. Warrants
NASDAQ · Healthcare · Biotechnology · US
$0.03
+2408.33%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +91.2%
- EBIT
- +21.4%
- EPS
- +78.1%
- Free cash flow
- +6.7%
- Operating cash flow
- +6.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +66.7%
- EBIT
- +9.3%
- Net income
- +46.6%
- EPS
- +71.4%
- Free cash flow
- +5.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2025